Natural Killer Cell Based Non-Myeloablative Transplantation For Acute Myeloid Leukemia

Non-myeloablative transplantation provides a therapeutic strategy for treating patients with active infection who cannot tolerate conventional myeloablative transplantation using high-dose chemoradiotherapy. Besides having less side effects (due to chemo), I like this approach because haploidentical transplants using non-inherited maternal antigen (NIMA)-mismatched donors or natural killer (NK) alloreactive donors can greatly increase the donor availability and open a way to more appropriate donor selection in HLA-haploidentical HSCT. The following is a link to a clinical trial using these approaches.
NK Cell Based Non-Myeloablative Transplantation in (AML) Acute Myeloid Leukemia.

 

NEW! AML-MDS POP NOW AVAILABLE FOR DOWNLOAD


Speak Your Mind

*